Hong Kong Pharma Stock News

Alphamab Oncology recently announced that its drug candidate JSKN003 has received Fast Track Designation from the U.S. FDA for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, without restriction by HER2 expression. This regulatory milestone builds on promising international clinical trial data and highlights momentum in Alphamab's pipeline of antibody-based oncology therapies. We'll explore how the U.S. FDA's Fast...

China Overseas Property Holdings Limited announced that, following a board meeting on October 28, 2025, Mr. Pang Jinying resigned from his roles as Executive Director, Vice President, and alternate to the authorised representative due to a realignment of work duties. This departure marks a significant leadership transition and raises important considerations about continuity in management and overall corporate governance. We will assess how this key executive change could influence investor...

InnoCare Pharma recently announced two important milestones: the first patient was dosed in a Chinese clinical trial for its novel B7-H3 targeted ADC (ICP-B794), and encouraging new phase I/II clinical data on zurletrectinib for pediatric and adolescent solid tumors was shared at an international oncology congress. Of particular note, ICP-B794 addresses a significant unmet need as there are currently no B7-H3 targeted therapies approved for marketing globally, highlighting InnoCare’s focus...

Earlier this month, Dongfang Electric Corporation Limited released earnings results for the nine months ended September 30, 2025, reporting sales of CNY 54.74 billion and net income of CNY 2.97 billion, both higher than the same period last year. The company also announced plans to amend its Articles of Association, with changes pending shareholder approval at an upcoming extraordinary general meeting. We'll explore how Dongfang Electric's strong earnings growth reinforces its investment...

Geely Automobile Holdings reported unaudited group vehicle sales for October 2025, delivering 307,133 units for the month and 2.48 million units year-to-date, both substantially higher than the corresponding periods last year. This sharp rise in sales volume highlights strong demand and could be seen as a reflection of Geely's expansion efforts and product appeal in an increasingly competitive market. We'll examine how Geely's record monthly and year-to-date sales performance informs its...

Ascletis Pharma announced positive Phase Ib results for its ASC30 oral and subcutaneous formulations, showing notable placebo-adjusted mean body weight reduction, a favorable safety profile, and ultra-long half-lives supporting both monthly and quarterly dosing, with these updates presented recently at ObesityWeek 2025. The company also unveiled new preclinical results where a combination of ASC47 and ASC31 outperformed monotherapies in promoting both weight and fat loss, and advanced its...

China Life Insurance reported earnings for the nine months ended September 30, 2025, with net income reaching CNY167.80 billion, up from CNY104.52 billion a year earlier, and basic earnings per share from continuing operations rising to CNY5.94. New agreements on insurance fund investment management and the renewal of key connected transactions reflect ongoing efforts to strengthen investment oversight and enhance compliance, potentially influencing operational efficiency. We'll examine how...

China XLX Fertiliser (SEHK:1866) has started a share buyback program after approval at its recent Annual General Meeting. The company now has permission to repurchase up to 10% of its outstanding shares. This move can boost earnings per share and reflects faith in the company's outlook. See our latest analysis for China XLX Fertiliser. After a sharp rally this year, China XLX Fertiliser’s share price has climbed 94.5% year-to-date. This reflects stronger sentiment and optimism following the...

China Resources Mixc Lifestyle Services (SEHK:1209) recently renewed several framework agreements with affiliated entities, covering procurement, value-added services, property management, and membership operations. These moves highlight the company's ongoing efforts to secure stable and recurring revenue streams while fostering reliable business relationships. See our latest analysis for China Resources Mixc Lifestyle Services. Momentum is clearly building for China Resources Mixc Lifestyle...

MMG (SEHK:1208) announced that Chairman and Non-Executive Director Mr. Xu Jiqing will step down on December 2, 2025. He will transition to a leadership role at China Minmetals Corporation. See our latest analysis for MMG. MMG’s leadership shake-up lands amid an impressive run, with its 90-day share price return standing at 65.6% and its total shareholder return for the year reaching 138.6%. Momentum has clearly accelerated as investors respond not only to the governance news but also to the...

Investors have been taking a fresh look at Hong Kong and China Gas (SEHK:3) as Beijing moves to secure natural gas supplies for winter, introduces renewable sources, and signals possible adjustments in urban gas pricing. At the same time, the company is gaining attention for its commitment to hydrogen energy. New pilot projects are aiming to position it at the forefront of green fuel technology. These factors appear to be shaping market sentiment around the stock as the broader sector...

Global markets have recently experienced a downturn, with U.S. equity indexes finishing lower amid concerns over elevated valuations and increased scrutiny on AI spending. Despite these broader market challenges, there remains an intriguing segment of the stock market that continues to capture investor interest: penny stocks. Although the term 'penny stock' might evoke images of past trading eras, these smaller or newer companies can still offer substantial growth opportunities when backed by...

COSCO SHIPPING Holdings (SEHK:1919) released its earnings for the nine months ended September 2025, revealing declines in both revenue and net income compared to the same period last year. Investors are watching closely to gauge what these results mean for the company’s direction. See our latest analysis for COSCO SHIPPING Holdings. Despite reporting lower earnings, COSCO SHIPPING Holdings’ recent momentum has surprised many. The company recorded a sharp 18.7% 30-day share price return and a...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Qatar Airways has fully exited its position in Cathay Pacific after selling its entire stake for approximately $897 million. As a result of this share buyback, Swire Pacific (SEHK:19) now sees its interest in the airline rise to nearly 48%. See our latest analysis for Swire Pacific. Swire Pacific's position in Cathay Pacific comes amid a year of shifting momentum. Even with some recent bumps, investors who stuck with the stock over the past year saw a 6.6% total return. Those with a five-year...

China Petroleum & Chemical (SEHK:386) just posted its third-quarter and nine-month financials, providing new insight into its 2025 performance. The results show a dip in sales and revenue, along with mixed net income trends. See our latest analysis for China Petroleum & Chemical. China Petroleum & Chemical’s latest financials just landed against a backdrop of modest share price momentum. After a sluggish few months, the stock pushed higher recently with a 4.38% one-month share price return...

As global markets navigate a period of volatility, with U.S. stocks experiencing a downturn amid concerns over AI spending and economic uncertainties, Asian markets have shown resilience, particularly in China where easing trade tensions have bolstered investor sentiment. In such an environment, growth companies with high insider ownership can be appealing as they often signal management's confidence in the business's long-term prospects and alignment with shareholder interests.

CARsgen Therapeutics Holdings (SEHK:2171) just shared clinical trial data on two of its allogeneic CAR-T cell therapies for heavily pretreated blood cancers. The results suggest progress and could bring renewed investor focus to the company’s pipeline. See our latest analysis for CARsgen Therapeutics Holdings. CARsgen’s positive clinical updates are catching attention, especially with the stock posting a 68% year-to-date share price return and an impressive 109% total shareholder return over...

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") below 12x, you may consider...

Unfortunately for some shareholders, the Virtual Mind Holding Company Limited ( HKG:1520 ) share price has dived 28% in...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Key Insights Significant control over WuXi Biologics (Cayman) by individual investors implies that the general public...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

With a price-to-earnings (or "P/E") ratio of 9.6x Zhongsheng Group Holdings Limited ( HKG:881 ) may be sending bullish...